Alnylam Pharma (ALNY) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results and Highlights Recent Period Progress
May 7, 2015 4:00 PM EDTLaunched Alnylam 2020 Guidance for Advancement and Commercialization of RNAi Therapeutics
Advanced Multiple Clinical Programs and Presented Evidence for Potential Disease-Modifying Activity for Patisiran in Familial Amyloidotic Polyneuropathy (FAP) and ALN-AT3 in Hemophilia
Plans to Present New Clinical Data for ALN-AT3 and Initial Clinical Data for ALN-CC5 in Oral Presentations at Medical Meetings in June
Maintained Strong Balance Sheet with $1.45 Billion in Cash and Expects to End 2015 with Greater than $1.2 Billion in Cash
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
